Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...
Share on Pinterest A new drug combo therapy significantly improved overall survival rates in males with locally advanced prostate cancer. Maskot/Getty Images A drug combination already used in ...
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...
177Lu-PSMA-617 combined with ADT and ARPI reduced progression or death risk by 28% in PSMA-positive mHSPC patients. The PSMAddition trial showed significant rPFS improvement and a positive OS trend, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results